Skip to main content
. 2020 Mar 12;8(1):e000713. doi: 10.1136/jitc-2020-000713

Figure 2.

Figure 2

(A) PD-L1 IHC by Dako 22C3 in baseline (left panel) and relapse (right panel) biopsy. (B) CD3 by immunohistochemistry in baseline (left panel) and relapse (right panel) biopsy.